Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on December 28, 2022. The registrant is a Delaware corporation with principal executive offices in Palo Alto, California. The report discloses the entry into a material definitive agreement regarding a consulting arrangement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the amended consulting fees:
- Current Monthly Fee (through Dec 31, 2022): £23,000
- New Monthly Fee (starting Jan 1, 2023): £35,000
- Termination Payment: 12 months of the monthly fee if terminated without cause.
Material Changes
The primary material change is the Third Amendment to the Consultancy Agreement with Prof. Jagdeep Nanchahal, entered into on December 28, 2022. Key changes include:
- Fee Increase: The monthly cash fee increases from £23,000 to £35,000 effective January 1, 2023.
- Adjustment Mechanism: Future fees will be adjusted yearly based on the UK consumer price index and the consultant's contributions, subject to Board or Compensation Committee recommendation.
- Termination Terms: A lump sum payment of 12 months' fees is now mandated if the Company terminates the agreement for any reason other than cause.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding the company's overall business strategy. The document focuses solely on the contractual amendment. No specific risks or contingencies beyond the standard contractual obligations of the consulting agreement are detailed in this report.
Investor Verification Checklist
- Verify the total annual cost increase resulting from the fee adjustment (£144,000 additional annual expense).
- Review the full text of the Third Amendment (Exhibit 10.1) for any additional clauses not summarized in the 8-K.
- Confirm the relationship between 180 Life Sciences Corp. and CannBioRex Pharma Limited to understand the subsidiary structure.
- Check subsequent filings for any further amendments to the compensation structure or termination events.